Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. - Wikidata - awgldk - TriplyDB

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.

http://www.wikidata.org/entity/Q38804680

about

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).Urgency to treat patients with chronic hepatitis C in Asia.Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.

P2860

Q33629092-01BE3C23-8194-4E6E-B4CA-BE2C95C23D12 Q33646482-45DC0DD8-A553-4980-9886-862CBABECD98 Q38946893-2CDEE644-B185-40AA-8A8E-398CBC54439B Q39016874-8EB9B48E-9842-4039-B99A-0F960B217B5E Q39049155-EDDF6C70-6DAE-4BDF-BE22-D020A311192F Q45324716-8B48B5EF-45A0-4283-AA19-DDA54538D8E1 Q47548651-5FCCB91C-122A-44E4-9DEB-1634E8D79AC1 Q47657221-5A257474-4A85-4511-A911-5DBB2A73D19B

P2860

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.

http://www.wikidata.org/entity/Q38804680

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Lower response to simeprevir a ...... compared with clinical trials.

@en

type

label

Lower response to simeprevir a ...... compared with clinical trials.

@en

prefLabel

Lower response to simeprevir a ...... compared with clinical trials.

@en

P1433

Q38804680-A2F16748-BA34-4663-B49F-F0E6958F22EF

P1476

Q38804680-12A82B94-C8BF-4A2E-8642-B7F8D7982A08

P2093

Q38804680-0EA667D5-EA63-4AF6-A47B-6A312CC5F4FE

Q38804680-11318AAA-29CC-4A08-91C3-A7D13A519E3A

Q38804680-51A4DF7A-2A72-4AAF-9C5B-5A30B94800A7

Q38804680-53091501-A6D8-4E95-8886-DFFB69CCFEC0

Q38804680-81546DE2-1381-48F1-96ED-30AADBD9A969

Q38804680-B90F30DA-7C79-4DBF-B863-793AC2A9676E

P2860

Q38804680-06BC0A8C-C002-4C0E-83EB-E9B67F2DA138

Q38804680-15D2788D-D0F0-496A-ADC3-DEC0BB62730C

Q38804680-18E4626B-5F2E-4A39-822A-4B3AB4BFA79E

Q38804680-1F19D585-297F-4C3E-8463-2C2FC1316E4B

Q38804680-2A43C6B6-2413-4346-9BC0-A49319BAB5D8

Q38804680-461C4938-757B-4032-9532-4A10B0937708

Q38804680-5B40B95A-48AF-49A1-AE06-8C235309C707

Q38804680-880FC25B-8E85-439F-A814-72FA465A795C

Q38804680-98AE60A7-8DC8-4F32-B2A6-F3A2803CBC00

Q38804680-A1F7EE8C-E8A9-45C3-ACF8-A56ABFD69C4F

P304

Q38804680-85F50ADC-42CE-4A79-846B-DCDE7F4CB315

P31

Q38804680-43C63FC8-23D3-478F-A003-6F07491586AE

P356

Q38804680-CEFEBB17-B9B9-423E-9EC8-1D5697DE1B1D

P433

Q38804680-C06967DB-3FCC-49D4-9FF9-D01AA30BCA62

P478

Q38804680-202A9FC4-CB3B-4F96-834F-52DD56CDD66E

P577

Q38804680-1D860F73-D632-4ABF-9F25-5E2864396CE6

P698

Q38804680-51D0D7CE-5057-4C6A-B1A5-B2BF5ED1CB13

P921

Q38804680-EEC72567-8DAB-49C1-8345-E128BBAAB424

P932

Q38804680-9CCF8E28-C7EA-4F1A-B608-B7FE98A4CC86

P356

BMJGAST-2015-000056

P1433

BMJ open gastroenterology

P1476

Lower response to simeprevir a ...... compared with clinical trials.

@en

P2093

Brittany E Yee

http://www.w3.org/2001/XMLSchema#string

Glen Lutchman

http://www.w3.org/2001/XMLSchema#string

Joseph K Lim

http://www.w3.org/2001/XMLSchema#string

Mindie H Nguyen

http://www.w3.org/2001/XMLSchema#string

Minjuan Jin

http://www.w3.org/2001/XMLSchema#string

Nghia H Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.

Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.

New hepatitis C therapies: the toolbox, strategies, and challenges.

P304

e000056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJGAST-2015-000056

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26966547

http://www.w3.org/2001/XMLSchema#string

P921

P932

4780041

http://www.w3.org/2001/XMLSchema#string